Loxl2 inhibition with simtuzumab attenuates extracellular matrix remodeling and preserves cardiac function in LMNA-associated dilated cardiomyopathy.
Does simtuzumab preserve cardiac function in LMNA mutation-induced dilated cardiomyopathy?
Loxl2 inhibition with simtuzumab represents a potential therapeutic strategy to preserve cardiac function in LMNA-associated dilated cardiomyopathy.
Taken together, our findings underscore the crucial role of Loxl2 as a therapeutic target and suggest that its inhibition could be a promising strategy to preserve cardiac function in LMNA-associated dilated cardiomyopathy.
Kervella et al. (2026) studied this question. Loxl2 inhibition with simtuzumab attenuates extracellular matrix remodeling and preserves cardiac function in LMNA-associated dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: